EyePoint Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

EyePoint

29/04/2024 14:44

* EyePoint Pharmaceuticals Inc  EYPT.OQ   EYPT.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 1 (estimated) for the period ending March 31 2024
    * The Watertown Massachusetts-based  company is expected to
report
a 29.1% increase in revenue to $9.917 million from $7.68 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for EyePoint Pharmaceuticals
Inc
is for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for EyePoint
Pharmaceuticals Inc is $46.00​, above​ its last closing price
of $16.75. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.46       -0.49      -0.33     Beat    32.1
 Jan. 1 0001   -0.54       -0.51      -0.33     Beat    35.7
 Jan. 1 0001   0.68                   -0.61             -201.9
                                                        ​
 Mar. 31 2023  -0.68       -0.68      -0.56     Beat    18
 ​​Dec.        -0.61       -0.61      -1.16     Missed  -90.2
 31 2022                                                
 Sep. 30 2022  -0.69       -0.70      -0.49     Beat    29.6​
 Jun. 30 2022  -0.52       -0.52      -0.52     Met     0.6
 Mar. 31 2022  -0.58       -0.58      -0.56     Beat    3.1
 This summary was machine generated April 29 at 13:44 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)